



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/532,258	10/02/2006	J. Keith Joung	62031(51588)	8615
71284	7590	01/20/2010	EXAMINER	
EDWARDS ANGELL PALMER & DODGE LLP			LIU, SUE XU	
P.O. BOX 55874			ART UNIT	PAPER NUMBER
BOSTON, MA 02205			1639	
MAIL DATE		DELIVERY MODE		
01/20/2010		PAPER		

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/532,258	JOUNG ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	SUE LIU	1639	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 01 October 2009.

2a) This action is **FINAL**.                            2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-7,9,10,12-35 and 37-39 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 1-7,9,10,12-35 and 37-39 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date <u>10/2/09</u> .	5) <input type="checkbox"/> Notice of Informal Patent Application
	6) <input type="checkbox"/> Other: _____ .

**DETAILED ACTION**

***Claim Status***

1. Claims 8, 11, 36 and 40-95 have been cancelled as filed on 10/1/09.  
Claims 1-7, 9, 10, 12-35 and 37-39 are currently pending.  
Claims 1-7, 9, 10, 12-35 and 37-39 are being examined in this application.

***Election/Restrictions***

2. Applicant's election with traverse of Group 1 (claims 1-39) in the reply filed on 8/28/08 is previously acknowledged.
3. Applicant's election of the following species:
  - A.) three zinc finger;
  - B.) Cys2His2;in the reply filed on 8/28/08 is previously acknowledged.

***Priority***

4. This application is filed under 35 U.S.C 371 of PCT/US03/34010 (filed on 10/23/2003), which claims priority to US provisional applications 60/420,458 (filed on 10/23/2002) and 60/466,889 (filed on 04/30/2003).

***Information Disclosure Statement***

5. The IDS filed on 10/2/09 has been considered. See the attached PTO 1449 form.

***Specification***

6. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification. MPEP 608.01.

***Claim Objection(s) / Rejection(s) Withdrawn***

7. In light of applicants' amendments to the claims, the objection against Claim 8 in the previous office action is withdrawn.

8. In light of applicants' amendments to the claims, the following claim rejection(s) as set forth in the previous office action is(are) withdrawn:

A.) Claims 1-39 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

B.) Claims 1-14, 16-19, 21-25, 27-29, 32, 34, 35 and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Isalan et al. (Nature Biotechnology. Vol.19: 656-660; 7/2001), in view of Isalan et al. (Biochemistry. Vol.37: 12026-12033; 1998; referred to as Isalan II).

C.) Claim 1 is provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 51 and 52 of copending Application No. 10/532,031 (PGPUB 20060246110; Now Abandoned).

**New/Maintained Claim Objection(s) / Rejection(s)**

***Claim Rejections - 35 USC § 103***

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

10. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

*Isalan and Choo*

11. Claims **1-7, 9, 10, 12-14, 16-19, 21, 22, 26-29, 32-35** and **37** are rejected under **35 U.S.C. 103(a)** as being unpatentable over **Isalan** et al. (Nature Biotechnology. Vol.19: 656-660; 7/2001), and in view of **Choo** et al. (WO 00/27878; 5/18/2000). This rejection is necessitated by applicant's amendments to the claims.

The instant claims recite “A method of selecting a multi-zinc finger polypeptide that binds to a sequence of interest comprising at least two subsites, said method comprising the steps of:

a) incubating position-sensitive primary libraries with target site constructs under low-stringency conditions sufficient to form first binding complexes, wherein said primary libraries comprise multi-zinc-finger polypeptides having one variable finger and at least one anchor finger, and wherein the target site construct has one subsite with a sequence identical to a subsite

of the sequence of interest, and one or more subsites with sequences to which the anchor finger(s) bind with low affinity;

b) isolating pools comprising nucleic acid sequences encoding the multi-zinc-finger polypeptides having one variable finger, that formed in the first binding complexes of step a) with the target site constructs;

c) recombining the nucleic acid sequences encoding the one variable finger from the isolated pools of step b) to produce a secondary library encoding multi-zinc-finger polypeptides having zinc-fingers partially optimized for binding to subsites of the sequence of interest;

d) incubating the secondary library of step c) with the sequence of interest under high-stringency conditions sufficient to form second high-affinity binding complexes between the multi-zinc-finger polypeptides and the sequence of interest; and

e) isolating nucleic acid sequences encoding multi-zinc-finger polypeptides that formed in the second binding complexes of step d)."

Isalan et al, throughout the publication, teach methods of generating recombinant zinc fingers based on selecting mutant zinc finger proteins that bind to a predetermined nucleic acid sequence (e.g. Abstract; pp.656+).

For **claim 1** step a): "*incubating position-sensitive primary libraries with target site constructs under low-stringency conditions sufficient to form first binding complexes, wherein said primary libraries comprise multi-zinc-finger polypeptides having one variable finger and at least one anchor finger, and wherein the target site construct has one subsite with a sequence identical to a subsite of the sequence of interest, and one or more subsites with sequences to which the anchor finger(s) bind with low affinity*": This method step is interpreted to mean binding libraries of zinc finger containing proteins to nucleic acid target constructs containing "an anchor site" and a site with a nucleic acid "sequence of interest" (or a predetermined nucleic acid sequence). The reference teaches generating libraries (at least two libraries) of randomized

zinc finger proteins, where a wildtype finger is combined with two randomly mutated zinc fingers (e.g. Figure 1; pp.656-657), which the wildtype finger reads the “anchor finger” and the mutated fingers read on the “variable finger”. The reference also teaches binding the said libraries of zinc finger proteins to a construct comprising a “predetermined DNA sequence” (e.g. p.657; Figure 2; Table 1 shows an example of using a HIV promoter sequence as the predetermined DNA sequence) and a segment of DNA sequence that binds to the wild-type zinc finger, which the predetermined DNA sequence reads on “a sequence of interest”, and the wild-type zinc finger binding sequence reads on the “anchor finger” binding sequence. The instant specification broadly defines the term “position-sensitive” (e.g. Spec. p.6, lines 5+), which can be reasonably interpreted to be any zinc finger libraries that have multiple zinc finger domains (that may have interactions). The reference teaches the generated zinc fingers of the proteins interact with other to achieve “comprehensive DNA recognition” (e.g. p.657), which reads on the inherent property of “position-sensitive”.

The instant specification broadly defines the term “low stringency” to “conditions” “which are conducive to the formation of ‘binding complexes’ comprising both weakly- and strongly-bound proteins and nucleic acids” (spec. PGPUB, [0073]), which definition broadly encompass any condition depending on the point of reference. Similarly, the term “high-stringency conditions” is defined as conditions “which are conducive to the formation of ‘high affinity binding complexes’ comprising only strongly-bound proteins and nucleic acids.” (spec. PGPUB, [0073]), which is also a broad and relative definition. For example, a condition can be considered to be both “low” and “high” stringency depending the point of reference. That is comparing to another lower stringency condition, a condition maybe considered “high”, and

comparing to a higher stringency condition, the same condition maybe considered “low”. Thus, the selection conditions taught in the Isalan reference can be considered as either low or high stringency condition.

Similarly, the instant specification also broadly defines the phrases “low” and “high” affinity” in relative terms. The instant specification recites “Two molecules that bind strongly to each other have a ‘high affinity’ for each other, while molecules that bind weakly to each other have a ‘low affinity’ for each other.” (Spec., PGPUB, [0063]). These said definitions given the broadest and reasonable interpretation can encompass any “affinity”, because any given affinity can be considered as either “low” or “high” depending on the point of reference. The reference teaches the “anchor finger” and the “variable finger” have affinity to their binding sites (as exhibit through binding interaction; e.g. p.658, left col.), and thus the reference’s teachings read on the “low affinity” or “high affinity” binding. In addition, the reference teaches the anchor fingers to be of the same structure as the instant claimed anchor finger (which is also derived from Zif268), and thus the reference’s teachings read on the inherent properties of low affinity and/or specificity.

For **claim 1** step (b): *“isolating pools comprising nucleic acid sequences encoding the multi-zinc-finger polypeptides having one variable finger, that formed in the first binding complexes of step a) with the target site constructs”*: The instant claim 1 step (b) is interpreted to mean isolating nucleic acids (molecules) that encode for the zinc finger proteins that bind to the “target site constructs”. The reference teaches isolating or selecting the polypeptides that bind to

the target constructs through, for example, phage display selection (e.g. Figure 1; p.657), which the selected phage would comprise the DNA encoding for the selected zinc finger polypeptides.

**For claim 1** step (c): *“recombin[ing] the nucleic acid sequences encoding the one variable finger from the isolated pools of step b) to produce a secondary library...”*: The reference teaches recombining the DNA sequences (encoding for the zinc finger polypeptides) of the selected two libraries of zinc fingers (e.g. Figure 1; p.657, left col.), which the resulting library (read on the secondary library) would inherently be “partially optimized for binding...”

**For claim 1** step (d): *“incubat[ing] the secondary library of step c) with the sequence of interest under high-stringency conditions sufficient to form second high affinity binding complexes...”*: The reference also teaches binding the recombined zinc finger polypeptides with the predetermined sequence through additional rounds of selection (e.g. Figure 1; Table 1; pp.657-658), which selection would inherently result in high affinity binding proteins (see more discussion above).

**For claim 1** step (e): *“isolat[ing] nucleic acid sequences encoding multi-zinc finger polypeptides that formed in the second binding complexes...”*: The reference teaches isolating nucleic acids (molecules) that encode for zinc finger proteins that bind to the predetermined sequence of interest (e.g. pp.657+; Figure 1).

**For claims 2 and 3:** The reference teaches at least two or three zinc fingers (e.g. Figures 1 and 2).

**For claim 4:** The reference teaches the target construct having the predefined sequence (or DNA sequence of interest) (e.g. Figure 2; Table 1).

**For claim 5:** The reference teaches various numbers base pairs (such as 3 bps) at the zinc finger binding DNA sequence (e.g. Figure 2 and Table 1).

**For claims 6 and 7:** The reference teaches various numbers (such as 3 sites for three fingers) of binding sites (e.g. Figure 2 and table 1).

**For claim 9:** The reference teaches the wild-type target site (the anchor finger binding sequence) comprises sequence of GCC (e.g. Figure 2A where the binding sequence for Lib23).

**For claims 10, 12-14 and 16-19:** The reference teaches the library of zinc finger proteins comprise wildtype finger sequence from a naturally occurring zinc finger protein, Zif268 (e.g. p.657) as well as phage displayed mutant Zif268 zinc finger proteins (i.e. synthetic derivative) (e.g. Figure 1).

**For claims 21 and 22:** The reference teaches randomizing at least the residues within the  $\alpha$ -helical region of the zinc fingers (e.g. Figure 2).

**For claims 27, 28, 34 and 35:** The reference teaches expressing the zinc finger library in bacteriophage system (e.g. p.659).

**For claims 29 and 37:** The reference teaches incubating the phage displayed proteins with the target constructs in test tubes (i.e. in vitro) (e.g. p.660).

**For claim 32:** The reference teaches using PCR to recombine the two libraries of genes encoding for the zinc finger proteins. (e.g. p.660).

Isalan et al do not explicitly teach using “low stringency conditions” and using a low affinity anchor finger binding sequence (nucleic acid constructs) in the first rounds of selection,

and later using “high stringency conditions”. However, the reference inherently teaches using low or high stringency conditions or using low affinity sequences as discussed supra.

Alternatively, **Choo** et al., throughout the publication, teaches various methods of generating mutant zinc finger protein libraries, and methods of screening the libraries (e.g. Abstract). The reference teaches using various screening/selecting conditions including both high and low stringencies so that high or low affinity binding protein can be selected (e.g. pp.27+). The reference also discusses various conditions such as buffer concentrations for different selections (including different ionic strength, detergent concentrations, etc.; pp.25+), which encompass low and/or high stringency conditions. The Choo reference also teaches selection for “low to medium affinity zinc finger polypeptides can be selected” and they “can be superior candidates for generating very high affinity zinc finger polypeptides” in an “affinity sharpening” process through subsequent rounds of selections (e.g. p.27, lines 6+; p.29, lines 15+). The reference also teaches low affinity “target nucleic acids” can be used “to enrich for library members” with “relatively low affinity” (e.g. p.29, lines 9+).

Therefore, it would have been *prima facie* obvious for one of ordinary skill in the art at the time the invention was made to use various desired selection conditions (low or high stringency) as well as nucleic acid binding constructs to select zinc finger proteins with desired binding affinity.

A person of ordinary skill in the art would have been motivated at the time of the invention to use low stringency conditions with low affinity binding constructs (for the anchor finger) to conduct the initial round of zinc finger protein selection, because Choo et al. teach the advantages of selecting under low stringency condition so that zinc finger with low to medium

affinity can be isolated to increase the potential pool of zinc finger protein candidates, as discussed supra. Because the cited references teach methods of selecting/screening zinc finger proteins under various conditions for the purpose of isolating zinc finger with desired binding affinity and specificity, it would have been obvious to one skilled in the art to substitute one selection condition (high stringency) for the other (low stringency) to achieve the predictable result of selecting/screening the desired zinc finger protein.

A person of ordinary skill in the art would have been motivated at the time of the invention to use high stringency conditions to conduct the subsequent rounds of zinc finger protein selection to select for high affinity binding zinc fingers, because Choo et al. teach the advantages of “affinity sharpening” by increasing the selection stringency so that zinc finger with high affinity can be isolated. Thus, it would have been obvious to one of ordinary skill in the art to apply the standard technique of selecting zinc finger proteins using various selection conditions as taught by both Isalan and Choo, to improve zinc finger selection assays for the predictable result of enabling standard zinc finger protein selection/screening through binding assays. Therefore, it would have been obvious to a person of ordinary skill in the art to try various combinations of the known conditions and/or nucleic acid binding constructs for selecting zinc finger binding proteins, in an attempt to optimize zinc finger protein screening depending on the needs of various routine experimental designs, as a person with ordinary skill has good reason to pursue the known options within his or her technical grasp.

A person of ordinary skill in the art would have reasonable expectation of success of achieving such modifications since the cited references have demonstrated the success of generating various zinc finger protein libraries (or their encoding nucleic acids), using various

target binding constructs, using various binding conditions, etc., for selecting the desired zinc finger proteins.

In addition, Isalan et al. do not explicitly teach the libraries of proteins are expressed in vitro as recited in **clms 26 and 33**.

However, **Choo** et al., throughout the publication, teaches various methods of generating mutant zinc finger protein libraries, and methods of screening the libraries (e.g. Abstract). The reference teaches using in vitro polysome display of zinc finger proteins (e.g. p. 22; p.24), which the zinc finger polypeptides are produced in vitro using an in vitro transcription/translation system. The reference also teaches the in vitro protein production method offers various advantages such as improved affinity screening (e.g. p.23, lines 10+).

Therefore, it would have been *prima facie* obvious for one of ordinary skill in the art at the time the invention was made to generate mutant zinc finger proteins using in vitro expression.

A person of ordinary skill in the art would have been motivated at the time of the invention to use in vitro expression to produce mutant zinc finger proteins, because Choo et al. teach various advantages of in vitro expression such that a convenient and improved affinity screening methods can be used. In addition, because all of the cited references teach methods of producing mutant zinc finger proteins using various routine and known expression methods, it would have been obvious to one skilled in the art to substitute one expression method (*in vivo* production) for the other (*in vitro* production) to achieve the predictable result of expressing the desired zinc finger proteins.

A person of ordinary skill in the art would have reasonable expectation of success of achieving such modifications since all of the cited references have demonstrated the success of generating randomized/mutant zinc finger protein libraries using various protein production techniques.

*Isalan, Choo and Isalan II*

12. Claims **1-7, 9, 10, 12-14, 16-19, 21-29, 32-35** and **37** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Isalan** et al. (Nature Biotechnology. Vol.19: 656-660; 7/2001), in view of **Choo** et al. (WO 00/27878; 5/18/2000) and Isalan et al. (Biochemistry. Vol.37: 12026-12033; 1998; referred to as **Isalan II**).

Isalan et al, and Choo et al., teach methods of generating recombinant zinc fingers based on selecting mutant zinc finger proteins that bind to a predetermined nucleic acid sequence, as discussed supra. The teachings of the Isalan and Choo references as discussed above are hereby incorporated by reference in their entirety.

The combination of Isalan and Choo does not explicitly teach between 16 to 20 amino acids are represented at each of the randomized positions as recited in **clms 23-25**.

However, **Isalan II**, throughout the publication, teach generating various zinc finger proteins using phage display technology (e.g. Abstract). The reference teaches randomizing the desired positions in the zinc finger region (e.g. p.12027). The reference also teaches generating codons for all 20 amino acid residues (e.g. p.12028, left col.). The reference also teaches the need to generate diverse amino acid sequence for the selection process (e.g. 12026).

Therefore, it would have been *prima facie* obvious for one of ordinary skill in the art at the time the invention was made to generate randomized zinc finger protein libraries comprising various number of possible amino acid residues at each randomized position.

A person of ordinary skill in the art would have been motivated at the time of the invention to represent the desired number of amino acids at each randomized positions in a zinc finger, because Isalan II teaches the need to generate randomized zinc finger proteins with diverse sequences and it is routine and known to generate libraries that represent various number of amino acids (such as all 20 amino acids). In addition, because both the Isalan references teach methods of generating randomized zinc finger libraries with random amino acid mutation at various positions within the  $\alpha$ -recognition region for various screening purposes, it would have been obvious to one skilled in the art to substitute one set of amino acids (that are represented at each position; such as 8 different amino acids) for the another set (such as 16 to 20 amino acids) to achieve the predictable result of generating libraries of randomized zinc fingers representing various amino acids at the mutated positions.

A person of ordinary skill in the art would have reasonable expectation of success of achieving such modifications since all of the cited references have demonstrated the success of generating randomized zinc finger protein libraries with randomized positions representing the desired number amino acids.

*Isalan, Choo, Isalan II and Joung*

13. Claims **1-7, 9, 10, 12-14, 16-19, 21-35** and **37-39** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Isalan** et al. (Nature Biotechnology. Vol.19: 656-660; 7/2001), Isalan et

al. (Biochemistry. Vol.37: 12026-12033; 1998; referred to as **Isalan II**) and **Choo** et al. (WO 00/27878; 5/18/2000), as applied to claims 1-7, 9, 10, 12-14, 16-19, 21-25, 26-29, 32-35 and 37, and further in view of **Joung** et al. (PNAS. Vol.97: 7382-7387; 6/20/2000).

**Isalan** et al teach methods of generating recombinant zinc fingers based on selecting mutant zinc finger proteins that bind to a predetermined nucleic acid sequence, as discussed supra.

**Isalan II**, throughout the publication, teach generating various zinc finger proteins using phage display technology, as discussed supra.

**Choo** et al., throughout the publication, teaches various methods of generating mutant zinc finger protein libraries, and methods of screening the libraries, as discussed supra.

The combined teachings of the Isalan, Isalan II and Choo references as discussed above are hereby incorporated by reference in their entirety.

The combination of the Isalan, Isalan II and Choo references does not explicitly teach the libraries are incubated in cells as recited in **clms 30, 31, 38 and 39**.

However, **Joung** et al., throughout the publication, teach methods of generating randomly mutated zinc finger proteins and screening the zinc finger target binding in cells (e.g. Abstract). The reference teaches using a bacterial two hybrid system for zinc finger selection (e.g. Abstract; pp.7383). The reference also teaches the advantages of using such a system so that zinc finger proteins with high affinity can be isolated in a single selection step, and thus allowing a more rapid screening process (e.g. Abstract). The reference also teaches using various selection conditions to select for zinc finger proteins that bind to the target sites (e.g. pp.7383+). The

reference also teaches the selection system used is under “stringent standard” and “account for why we isolated such a small number of specific candidates”.

Therefore, it would have been *prima facie* obvious for one of ordinary skill in the art at the time the invention was made to screen for zinc finger polypeptides using an *in vivo* bacterial system and performing the selection process under high stringency.

A person of ordinary skill in the art would have been motivated at the time of the invention to using a bacterial cell based selection system to screen for target binding zinc finger proteins, because Joung et al. teach the advantages of using a bacteria call based system so that zinc finger proteins with high affinity can be isolated in a single selection step, and thus allowing a more rapid screening process. In addition, because all of the cited references teach methods of screening mutant/randomized zinc finger proteins for binding to nucleic acid targets of interest using various screening techniques, it would have been obvious to one skilled in the art to substitute one screening strategy (*in vitro* affinity assay) for the other (*in vivo* bacteria cell based 2 hybrid system) to achieve the predictable result of selecting for desired zinc finger proteins.

A person of ordinary skill in the art would have been motivated at the time of the invention to select zinc finger proteins under high stringency to obtain high affinity binding proteins, because Joung et al. teach the need to perform the selection under high stringency so that zinc finger proteins with high affinity and specificity can be obtained. Thus, it would have been obvious to one of ordinary skill in the art to apply the standard technique of screening/selecting zinc finger proteins under various conditions, to improve and/or optimize the screening/selection assay for the predictable result of enabling standard protein selection that

would result in desired proteins with the desired binding affinity/specificity for targets of interest.

A person of ordinary skill in the art would have reasonable expectation of success of achieving such modifications since all of the cited references have demonstrated the success of generating selecting various mutant/randomized zinc fingers using various protein production techniques under various conditions.

*Isalan, Choo, Isalan II, Joung and Chandrasegaran*

14. Claims **1-7, 9, 10, 12-35** and **37-39** are rejected under 35 U.S.C. 103(a) as being unpatentable over **Isalan** et al. (Nature Biotechnology. Vol.19: 656-660; 7/2001), Isalan et al. (Biochemistry. Vol.37: 12026-12033; 1998; referred to as **Isalan II**), **Choo** et al. (WO 00/27878; 5/18/2000) and **Joung** et al. (PNAS. Vol.97: 7382-7387; 6/20/2000), as applied to claims 1-7, 9, 10, 11-14, 16-19, 21-35 and 37-39, and further in view of **Chandrasegaran** (US 6,265,196; 7/24/2001).

**Isalan** et al teach methods of generating recombinant zinc fingers based on selecting mutant zinc finger proteins that bind to a predetermined nucleic acid sequence, as discussed supra.

**Isalan II**, throughout the publication, teach generating various zinc finger proteins using phage display technology, as discussed supra.

**Choo** et al., throughout the publication, teaches various methods of generating mutant zinc finger protein libraries, and methods of screening the libraries, as discussed supra.

**Joung** et al., throughout the publication, teach methods of generating randomly mutated zinc finger proteins and screening the zinc finger target binding in cells, as discussed supra.

The combined teachings of the Isalan, Isalan II, Choo and Joung references as discussed above are hereby incorporated by reference in their entirety.

The combination of the Isalan, Isalan II, Choo and Joung references does not explicitly teach the specific zinc finger sequence as recited in **clms 15 and 20**.

However, **Chandrasegaran**, throughout the patent, teach using various zinc finger protein with various amino acid sequences (e.g. Abstract). The reference specifically teaches using a zinc finger with amino acid sequence “QGGNLVR” for recognizing (or binding) the target sequence of GAA (e.g. col.22, Table 1), which the AA sequence matches SEQ ID NO:3. The reference also teaches designing zinc fingers with the appropriate amino acid sequence for binding to desired DNA target sequence of interest (e.g. col.16).

Therefore, it would have been *prima facie* obvious for one of ordinary skill in the art at the time the invention was made to generate zinc finger proteins comprising various amino acid sequences including sequences that are known to bind to certain target sites.

A person of ordinary skill in the art would have been motivated at the time of the invention to use generate zinc finger proteins to comprise a desired known sequence such as the sequence in SEQ ID NO:3, because Chandrasegaran teaches the sequence is known to bind to a specific target sequence and it is routine and known to alter the zinc finger sequences for binding to the desired target sites. In addition, because all of the cited references teach generating zinc finger proteins for binding to desired nucleic acid sequence of interest, it would have been obvious to one skilled in the art to substitute one known zinc finger sequence for the other to

achieve the predictable result of generating zinc finger polypeptide with the desired AA sequences.

A person of ordinary skill in the art would have reasonable expectation of success of achieving such modifications since all of the cited references have demonstrated the success of generating selecting various mutant/randomized zinc fingers using various protein production techniques under various conditions.

*Discussion and Answer to Argument*

15. Applicant's arguments have been fully considered but they are not persuasive for the following reasons (in addition to reasons of record). Each point of applicant's traversal is addressed below (applicant's arguments are in italic):

*Applicants argue “none of the cited references, alone or in any combination, teaches or suggests that two rounds of selection should be carried out...” (Reply, p.13.)*

Applicants are respectfully directed to the above new and/or modified rejection for discussion addressing the amended claims. Briefly, at least the Isalan reference teaches at least two rounds of selections, as discussed above. The Choo reference provides explicit motivation and guidance on multiple rounds of selection such as through the process of “affinity sharpening”.

*Applicants also traversed the above rejections over combinations of references by arguing each reference alone does not teach the claimed invention. (Reply, pp.13+).*

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

*Applicants also assert the Isalan II, Choo, Joung, or Chandrasegaran reference teaches away from the claimed invention. (Reply, pp.15-16).*

However, applicants have not provided any supporting evidence from the cited references to support the assertion of "teaching away." "The arguments of counsel cannot take the place of evidence in the record. In re Schulze, 346 F.2d 600, 602, 145 USPQ 716, 718 (CCPA 1965). Examples of attorney statements which are not evidence and which must be supported by an appropriate affidavit or declaration include statements regarding unexpected results, commercial success, solution of a long-felt need, inoperability of the prior art, invention before the date of the reference, and allegations that the author(s) of the prior art derived the disclosed subject matter from the applicant." (MPEP 716.01(c) II)

"Disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments. In re Susi, 440 F.2d 442, 169 USPQ 423 (CCPA 1971)." (see MPEP 2123).

Further, "the prior art's mere disclosure of more than one alternative does not constitute a teaching away from any of these alternatives because such disclosure does not criticize, discredit, or otherwise discourage the solution claimed...." In re Fulton, 391 F.3d 1195, 1201, 73 USPQ2d 1141, 1146 (Fed. Cir. 2004)." (see MPEP 2141.02).

In the instant case, none of the cited reference “criticize, discredit, or otherwise discourage” using low stringency conditions. In fact, the Choo reference as discussed above motivates one of the skill in the art to use low stringency condition for the initial rounds of selection so that a pool of low to medium affinity zinc fingers can be generated (see more discussion in the rejections).

*Applicants also assert hindsight reasoning. (Reply, p.21).*

In response to applicant's argument that the examiner's conclusion of obviousness is based upon improper hindsight reasoning, it must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971).

*Applicants also assert “there is no motivation in the cited art to combine the references...” (Reply, p.21).*

Applicants are respectfully directed to the Supreme Court decision, which forecloses the argument that a specific teaching, suggestion, or motivation is required in the references to support a finding of obviousness. *KSR*, 127 S.Ct. at 1741, 82 USPQ2d at 1396.

In addition, applicants are directed to the above modified rejections for reasoning and/or motivation statements to combine the cited references.

***Conclusion***

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sue Liu whose telephone number is 571-272-5539. The examiner can normally be reached on M-F 9am-3pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached at 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Sue Liu/  
Primary Examiner, AU 1639  
1/14/2010